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by the health insurer. The IT systems of health insurers and hospitals need to 
be adapted. RecommendAtions: A working group led by the pharma industry 
association and major health insurers (including pharma companies, hospital 
administration and oncologists) will set up pilots with oncology clinics to test 
the feasibility of implementing an indication code and work on sustainable pric-
ing models for TCRs. conclusion: Goal would be a standardised processing of 
the remuneration for TCRs based on indication code and the underlying pricing 
model. For scale up the FOPH would have to mandate the adoption of the approach 
at national level.
PHP331
Brexit and Grexit: imPlications for tHe PHarmaceutical industry
Hakim P1, Georgitseas N1, Degun R1, Suponcic S2
1Navigant Consulting Inc, London, UK, 2Navigant Consulting, Lawrenceville, NJ, USA
BAckgRound: The prospects of Brexit (UK exit from the EU) and Grexit (Greek exit 
from the Eurozone) have significant implications for the European pharmaceutical 
industry. In recent years, exiting the EU has been actively debated in the UK. While 
not a member of the Eurozone, the UK is a key member of the EU trade bloc. The 
UK government plans to hold a referendum by 2017; recent polls indicate 35-45% 
of Brits support withdrawal. In contrast, Greek withdrawal from the Eurozone may 
occur if the government is unable to reach an agreement with their creditors on 
the repayment of Greek sovereign debt. Failure to meet a € 1.6 billion payment to 
the IMF at the end of June 2015 may result in Eurozone withdrawal. impAct: As 
an EU member state, the UK forms a significant component of international refer-
ence pricing baskets for many other states; an arrangement which may or may not 
continue in the event of Brexit. Despite the independence of the British pound, 
Brexit may lead to further regional price disparity due to currency fluctuations. 
Both Brexit and Grexit are likely to have a significant impact on parallel trade 
amongst EU member states (parallel imports represent ~20% of UK drug sales, 
whereas exports for parallel trade account for ~12% of the Greek pharmaceutical 
market). Additionally, Grexit may impact the purchasing power of Greeks and their 
government’s ability to fund healthcare access to medicines. methodology: 
Navigant conducted qualitative interviews with payers and budget holders to 
understand expectations of the impact of Grexit and Brexit, anticipated strate-
gies in response to these withdrawals, the level of disruption to pharmaceutical 
supply and potential drug shortages. conclusions: Additional monitoring and 
appropriate planning is essential. The high level of uncertainty requires further 
consideration; Brexit and Grexit present significant implications to a broad array 
of stakeholders.
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BAckgRound: There are differences across the world in the definitions used to 
classify an orphan drug (OD), especially with respect to the prevalence of the dis-
ease justifying the orphan status and, the estimation of the population affected 
by the disease. oBjective: To identify the number of medicines which have been 
granted orphan designation in the United States (US) and European Union (EU), 
and analyse the approval trends over a ten-year time horizon. methods: All ODs 
authorised by the European Medicines Agency (EMA) and approved by the US Food 
and Drug Administration (FDA) were identified on the 1st May 2015 by downloading 
the databases available from their respective websites. Duplicates were removed 
in both cases using non-proprietary name and the lists were filtered to capture 
the period from 01/01/2005 to 31/12/2014. Results: The databases downloaded 
from the EMA and FDA had n= 93 and n= 237 results respectively. Removing the 
duplicates reduced these to n= 91 and n= 197 respectively. Filtering the list to select 
ODs authorised between the 01/01/2005 and 31/12/2014 gave final values of n= 74 and 
n= 189 respectively. ANALYSIS: The number of ODs approved significantly increased 
in numbers between the years 2005 and 2014 in the US and in the EU. In 2014 the 
EMA authorised 5 times as many ODs as they did in 2005 (15 vs 3 respectively) and 
a similar trend was observed in the US, where in 2014 the FDA authorised twice 
as many ODs as they did in 2005 (30 vs 14). conclusions: In 2005 the number of 
ODs authorised was significantly lower than that of 2014 and the designation of 
orphan diseases and approval of ODs was rare. 10 years on and gaining OD status 
for a sub population based rare disease appears from the outside to have become 
an objective for a number of pharmaceutical companies.
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oBjectives: To evaluate the potential for RSA implementation in Bulgaria and to 
outline the necessary legislative changes. methods: A literature review of the 
existing in EU RSA schemes and review of the local legislation were done to identify 
the laws and regulations intended for changes. Results: Bulgarian government has 
recently carried out major changes within the Health Insurance Act. The adopted 
texts introduced a “no discount - no reimbursement” rule, creation of HTA body 
and formal HTA assessment for all new and existing medicines with re-assessment 
every three years. The new HTA body is expected to adopt a threshold for cost-
effectiveness. Companies will be allowed to provide discounts for new medicines 
before reimbursement decision hence to influence the cost-effectiveness. The new 
measures are focusing mainly on the prices of the medicines, as were the old one 
(voluntary discounts to NHIF). The National Health Insurance Fund (NHIF) should 
consider other options which will give them opportunity for broader based negotia-
tions with the MAHs. As such option could be considered the implementation of RSA 
ance. conclusions: The following of protocols and guidelines for hernia repair 
has been shown to improve patient outcomes and reduce costs but the degree of 
uptake is variable. This suggests that there is scope for greater protocol/guideline 
adherence and resultant cost savings in hernia repair
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oBjective: France has large markets for pharmaceuticals in Algeria; moreover, 
Algerian authorities look to France for reference pricing. In recent times, the HAS 
is increasingly the influential health technology assessment (HTA) agency. French 
speaking countries are referencing and following the HAS decisions. The main objec-
tive of this study is to assess the HAS influence in North Africa region (Morocco, 
Algeria, Tunisia) in their reimbursement decisions. method: To have a comprehen-
sive study, a sample of medicines was determined, and these drugs had obtained 
positive recommendation by HAS during a period from January 2013 to December 
2013.Then, the recommendation from HAS were matched with the North African 
decision. Result: Total drugs approved for their first inscription were 258, where 
one drug obtained ASMR II, 12 obtained ASMR III, 13 noted ASMR IV and 232 ASMR 
V. When we have analyzed the common reimbursement decision taken according 
the level of ASMR We have observed that Morocco reimburse the drugs product with 
ASMR III and ASMR IV. However Algeria and Tunisia reimburse less the medicines 
with ASMR IV and V conclusion: This study demonstrates that the discordance 
between countries reimbursement decisions. In most cases it may reflect the dif-
ferences in the decision making process and in their constraint budget: Payers in 
Morocco are following HAS recommendation whereas Tunisia and Algeria there are 
following less HAS decisions.
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BAckgRound infoRmAtion: In 2014, Romania adopted a new legislation requiring 
Health_Technology_Assessment (HTA) as mandatory step in the drug reimbursement 
listing. The HTA System is a score-card, the drug/ a certain indication can be 
unconditional (80 – 145 points), or conditional approved (60-79 points). Conditional 
approved indications are reimbursed only if they are included in a cost-volume/cost-
volume-result contract (CV/CVR) with the National Payer,- requiring the tracking of 
drug utilisation data on indication. This could lead to differentiated pricing, depend-
ing on the benefit the product provides in different indications (Multiple Indication 
Pricing-MIP). One single unit price could be not relevant for all indications (e.g in 
oncology), especially when the same drug has both unconditional and conditional 
reimbursement. AppRoAch: Under MIP, drug utilisation would be tracked; the price 
of medicine per indication would be defined according to the benefit of the drug 
in that indication. Two approaches could be used: leverage existing national data 
collection by the National Payer, additionally collecting data like indication, treat-
ment status, result, etc. by a separate module in the Hospital Information System 
or use e-health/electronic patient records. Implications: Required minimum data 
fields, data format and attributes must be defined. Data must be complete, con-
sistent, available, allowing for validity checks. Marketing Authorization Holder 
(MAH) must receive reports containing information (anonymised and aggregated) 
on drug utilisation. To be defined: timing between data capturing and data avail-
ability, timing for paybacks, absorption of costs for data generation and capturing, 
error handling. RecommendAtions: Conduct pilot with a representative oncology 
clinic, set a methodology for collection, validation and use of data, generate reports, 
demonstrate the utility in managing CV/CVR. Scale up the project at national level 
through the National_Health_Insurance_House. conclusion: Developing a system 
to identify drug utilisation on indication, could support implementing conditional 
reimbursement schemes by the Payer and increase patient access to drugs.
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BAckgRound infoRmAtion: Targeted Combination Regimes (TCRs) could sig-
nificantly improve outcomes for cancer patients in future as drugs with different 
and complementary mechanisms of action often act synergistically to improve 
treatment results. Despite the potential benefits of TCRs there are also chal-
lenges associated with them. Several combination therapies involve more than 
one Marketing Authorization Holder, adding the cost of two medicines on top of 
each other combined with potentially longer therapy duration could make the 
funding of such TCRs unsustainable. The Federal_Office_of_Public_Health (FOPH) 
currently commands price negotiation at brand level, resulting in a single price per 
product, however in the future a more flexible pricing system might be required 
in order to enable fast patient access while making sure TCRs remain effective, 
expedient and economical. AppRoAch: One approach could be the introduction 
of an indication code on the billing process. The indication code could help health 
insurance companies to identify TCRs and allow a fast reimbursement through a 
simple and standardised process. Flexible pricing models would make sure that 
TCRs remain economical. implications: Patients would have to agree that infor-
mation on their condition (e.g. indication, molecular profile, therapy) would be 
captured on the billing process. The indication code would have to be encrypted 
